Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAGOON phase 3 trial of lurbinectedin with or without irinotecan versus investigator's choice in relapsed small cell lung cancer
MOH_2023-05-31_012697Phase 3Not yet recruiting
- Sponsor
- PharmaMar
- Start
- Apr 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin, irinotecan and topotecan in small cell lung cancer (SCLC) (3 arms), sponsored by PharmaMar. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
lurbinectedinirinotecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2023-05-31_012697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-31_012697.